Casgevy's Rollout: The World's First CRISPR Medicine Is Reaching Patients
By Sanna the Weaver • Thu Feb 12 2026 • Health
When the FDA approved Casgevy in December 2023, it was described as a historic moment — the first medicine in history to use CRISPR gene editing in a living patient, offering a functional cure for sickle cell disease and transfusion-dependent beta thalassemia. Eighteen months later, in mid-2025, the first patients in the United States began receiving treatment. By early 2026, more than 60 patients have been treated across US and UK authorized centers, and the real-world results are validating the clinical trial data: approximately 90% of treated sickle cell patients have been free of the severe pain crises that define the disease. How Casgevy Works Casgevy uses CRISPR-Cas9 to edit a patient's own stem cells, reactivating the production of fetal hemoglobin — a form of hemoglobin that functions normally even in the presence of the genetic mutation that causes sickle cell disease. The process requires harvesting stem cells from the patient's bone marrow, editing them in a laboratory, destroying the patient's existing bone marrow with chemotherapy, and transplanting the edited cells back. It is a lengthy, physically demanding process — patients typically spend four to six weeks in a specialized treatment center — but it offers what conventional treatments cannot: the possibility of living without the disease rather than managing it. The $2.2 Million Question Casgevy is priced at $2.2 million per patient in the United States. This makes it one of the most expensive medicines ever approved. Vertex and its co-developer CRISPR Therapeutics have argued that this price is justified by the lifetime cost of managing sickle cell disease without the cure — including hospitalizations, blood transfusions, chronic pain management, and lost productivity — which can exceed $2 million over a patient's lifetime. The economic argument is defensible on paper. The practical reality is that most patients with sickle cell disease are Black Americans covered by Medicaid, and state Medicaid programs are in active negotiations with Vertex about access terms. As of March 2026, reimbursement has been confirmed in only a handful of states. "We have cured sickle cell disease. We have not yet solved how to get that cure to the people who have it." — Sickle Cell Disease Association of America, January 2026 What Comes Next for CRISPR Medicines Casgevy's rollout, despite its access challenges, is establishing the clinical and regulatory infrastructure for the generation of CRISPR medicines that will follow it. More than 20 CRISPR-based therapies are in clinical trials in 2026, targeting conditions including Huntington's disease, transthyretin amyloidosis, various cancers, and HIV. The manufacturing expertise, treatment protocols, and regulatory pathways developed for Casgevy will accelerate all of them. The question of price and access — who pays, who benefits, and on what terms — will define the social contract around genetic medicine for a generation.